SCHEMBL14967006

SCHEMBL14967006

CC1(C)OC(c2ccco2)OC1(C)C

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.42
NPSR1 Q6W5P4 2/20 0.40
KDM4E B2RXH2 1/20 0.40
CHRM5 P08912 9/20 0.38
CHRM3 P20309 9/20 0.38
CHRM2 P08172 8/20 0.38
CHRM4 P08173 8/20 0.38
CHRM1 P11229 8/20 0.38
ALDH1A1 P00352 4/20 0.38
POLB P06746 3/20 0.37
MAPT P10636 2/20 0.37
KMT2A Q03164 2/20 0.37
TDP1 Q9NUW8 1/20 0.37
CPB1 P15086 1/20 0.36
CYP2C19 P33261 1/20 0.36
TP53 P04637 1/20 0.36
APOBEC3A P31941 1/20 0.36
CTDSP1 Q9GZU7 1/20 0.36
APOBEC3G Q9HC16 1/20 0.36
MEN1 O00255 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18963329 0.74 NPC1 (0.42) NPC1NPSR1KDM4ECHRM5CHRM3
SCHEMBL18963354 0.71 ALDH1A1 (0.43) NPC1NPSR1KDM4ECHRM5CHRM3
SCHEMBL509970 0.68 POLB (0.44) NPC1NPSR1KDM4ECHRM5CHRM3
SCHEMBL4558468 0.67 KDM1A (0.48) NPC1NPSR1KDM4ECHRM5CHRM3
SCHEMBL13380972 0.67 POLB (0.47) NPC1NPSR1KDM4ECHRM5CHRM3
SCHEMBL28078911 0.67 POLB (0.38) NPSR1KDM4ECHRM5CHRM3CHRM2
SCHEMBL5176857 0.66 NPC1 (0.40) NPC1NPSR1KDM4ECHRM5CHRM3
SCHEMBL17863581 0.66 MAPK1 (0.37) NPC1KMT2ACYP2C19MEN1MAPK1
SCHEMBL6376132 0.65 NPC1 (0.50) NPC1NPSR1KDM4ECHRM5CHRM3
SCHEMBL12619955 0.65 ALDH1A1 (0.48) NPC1NPSR1KDM4ECHRM5CHRM3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115353523-A Synthesis method of compound containing high-activity cyanomethyl 吉林大学 2022-11-18 CN claimed
CN-115353523-A Synthesis method of compound containing high-activity cyanomethyl 吉林大学 2022-11-18 CN disclosed
WO-2021114207-A1 PRODUCTION OF BENZENE DERIVATIVES RHODIA OPERATIONS (FR) 2021-06-17 WO disclosed
US-9206128-B2 Modulators of methyl modifying enzymes, compositions and uses thereof CONSTELLATION PHARMACEUTICALS, INC. (US) 2015-12-08 US disclosed
US-20140288123-A1 MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF CONSTELLATION PHARMACEUTICALS, INC. 2014-09-25 US disclosed
EP-2780014-A1 MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF Constellation Pharmaceuticals, Inc. (US) 2014-09-24 EP disclosed
WO-2013075083-A1 MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF CONSTELLATION PHARMACEUTICALS (US) 2013-05-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140288123-A1 MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF TET1, TET3, EHMT2 NPC1 4022/4885NPSR1 4719/4885KDM4E 76/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.